Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

We recently compiled a list of the Cathie Wood's Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics. CRISPR-Cas9, the CRISPR system that was awarded the Nobel Prize, allows us to “edit” genes in a targeted fashion, pinpointing a specific spot of the genome to be replaced by the ...